Ketamine Clinical Trials
Unraveling the Aesthetic Mind in Anhedonia, Insights From Pharmacological Imaging of the Human Brain: A Single-blind, Randomized, Placebo-controlled Cross-over Study
To see complete record on clinicaltrials.gov, please visit this link
Id: NCT05320107
Organisation Name: Medical University of Vienna
Overal Status: Recruiting
Start Date: June 1, 2022
Last Update: July 15, 2022
Lead Sponsor: Medical University of Vienna
Brief Summary: The aim of this study is to assess the impact of ketamine on aesthetic perception and processing. This study assesses the role of these effects in facilitating ketamine's antidepressant properties, with a focus on anhedonia. To address this aim, 25 patients with major depressive disorder and 35 healthy controls will be assessed twice with magnetic resonance imaging, once after administration of intravenous ketamine (subanesthetic dose) and once after administration of placebo.This study has a single-center, placebo-controlled, cross-over study design. During MRI, structural, resting state, and functional imaging will be performed. Functional imaging will comprise aesthetic processing, reward, and sexual arousal paradigms. In addition, various neuropsychological scales assessing depressive symptoms, anhedonia, and aesthetic processing will be performed. Eligibility for participation will be assessed during a screening visit, a follow up visit will end study participation.
Conditions:
- Major Depressive Disorder
Total execution time in seconds: 0.2111120223999